You are such a fool. A Stupid heggie is trying to make a dent on mantle cell indication for imbruvica. CLL is the main story as well as NHLs. Jnj still sucks with its management. I would be more aggressive as the CEO/MD.
EW is such a hidden misunderstood gem. I hope that EW stays independent.
more massive ramp up in revenue is coming. The intermediate risk patients in Europe will get Sapien 3 soon later this year. Expect Sapien 3 will be availabe for the intermediate risk patients in US in later next year. Expect the revenue of 260 millions per quarter to grow to 500 millions plus next year. what will happen to EW share price? To the moon. Virtually all these 80 year old patients are intermediate risk patients. Dr. Makkar of Cedar-Sinai said that TAVR will replace surgeries completely eventually. Latest Valve cost are around 40,000. Expect 80 billion markets worldwide with EW taking at least 65% of it. This translates to an annual run rate of 60 billions. And the Transcatheter Mitral valve will be approved in the next 2-3 years.
when market is up, EW is down. when market is down, EW is down. This is frustrating for the longs. Everyone is trying to get out.
anyone buying on the dip?
The growht of TAVR is actually running at 40% year to year in comparison.
I don't know why people are selling this at all. Fat margin and massive growth translates to profit per share to the sky. TAVR will be used for moderate risk patients (50% of patients plus) and high risk patients (30%). Eventually it will replace surgery. 220,000 thousand Aortic valve surgeries per year worldwide translates to 100 billions plus of opportunities for EW. 75% of it will translate to 75 billions per year of revenue. I did the same calculation for BLUE. Now Blue is 130 plus. EW gets 100 billions of opportunities per year. Blue only gets 1100 billions lifetime. Nothing beats EW in the biotech.
probably another Q like the one in oct. it will shoot to 160 after earnings. with all aortic valve procedures shifting toward tavr i won't be surprised that the earnings will blast off.
This valuation is too good to be true just like MDVN and PCYC last year. You have a multibillion dollar drug that will most likely be approved sooner than later. However, there are always doubters out there trying to trash talk it down for whatsoever reasons. pcyc at 90-85 was a no brainer. MDVN at 60 was a no brainer too. espr at 110-100 is a no brainer too. buy as much as you can while it lasts.
The problem with partnership is that it provides stability but at the same time takes away the immense upside on the stock price. I would rather tatke the risk and make a huge killings. BIIB is pretty much the same story. rcpt is the baby biib in the making.
There is no need to partner. They have enough money to run the trials. As phase 3 progresses they can sell for equities at 250/share or more. They can get one billion from doing another equities offer. This company will be at 40 billions or more upon approval of this drug. I kept saying that I as a CEO of a major pharma would be buying rcpt, espr, ttph, and insy. That would give me a 12 billions/year earning power for the next 12-16 years.
do you have one share shorted? I doubt that you can use your lunch money. It wasn't enoough.
buy as much as you can. there aren't that many shares available to buy. do not let these retail idiot shorts scare you. The fact is that there are only around 12 million shares floating and more than half of it is in the hands of big boys. Therefore, only a few shares are available to trade.
this company can go to mkt cap of 40 billions by retaining all the rights to all disease indications worldwide. No need to sell like pcyc who should have retained the shares to JNJ and pcyc could have been at 1000